GSK's herpes zoster vax candidate flies into Phase III; Sanofi Pasteur will begin shipping Fluzone;

> Researchers saw delayed tumor growth in mice given both an immune system booster and chemical counter to cancer's secretions. Story

> Sanofi Pasteur will begin shipping the Fluzone vaccine following an FDA licensure of the 2012-2013 formulation. Release

> The MVA85A tuberculosis vaccine is undergoing two Phase IIb proof-of-concept clinical studies. News

> Rotary Ghana and Rotary International have funded a vaccine cold room for the Greater Accra Regional Health Directorate. Item

> Chembio signed a $480,000 agreement with a Center for Disease Control contractor for an influenza immunity test. Article

> CSIRO, contracted by PATH, will produce antibodies for the development of new vaccines against rotavirus. More

And Finally... GlaxoSmithKline's ($GSK) herpes zoster vaccine candidate has commenced a global, randomized placebo-controlled Phase III clinical trial for the prevention of shingles in immunocompromised patients. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.